Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.

ABSTRACT:

Background

We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S-1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen.

Patients and methods

We retrospectively analyzed 727 APC patients who received first-line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in-group survival differences with monotherapy or combination therapy.

Results

The median surv

SUBMITTER: Huang PW 

PROVIDER: S-EPMC6745849 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature